Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PHLDB2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PHLDB2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PHLDB2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PHLDB2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PHLDB2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PHLDB2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PHLDB2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00443196 | Oral cavity | OSCC | wound healing, spreading of cells | 25/7305 | 34/18723 | 4.63e-05 | 3.90e-04 | 25 |
GO:00905056 | Oral cavity | OSCC | epiboly involved in wound healing | 25/7305 | 34/18723 | 4.63e-05 | 3.90e-04 | 25 |
GO:00020114 | Oral cavity | OSCC | morphogenesis of an epithelial sheet | 37/7305 | 57/18723 | 6.66e-05 | 5.38e-04 | 37 |
GO:006157220 | Oral cavity | OSCC | actin filament bundle organization | 87/7305 | 161/18723 | 7.49e-05 | 5.84e-04 | 87 |
GO:00905046 | Oral cavity | OSCC | epiboly | 25/7305 | 35/18723 | 1.02e-04 | 7.63e-04 | 25 |
GO:190303418 | Oral cavity | OSCC | regulation of response to wounding | 87/7305 | 167/18723 | 3.91e-04 | 2.38e-03 | 87 |
GO:00073697 | Oral cavity | OSCC | gastrulation | 95/7305 | 185/18723 | 4.17e-04 | 2.54e-03 | 95 |
GO:00301983 | Oral cavity | OSCC | extracellular matrix organization | 146/7305 | 301/18723 | 4.67e-04 | 2.77e-03 | 146 |
GO:0085029 | Oral cavity | OSCC | extracellular matrix assembly | 29/7305 | 45/18723 | 4.85e-04 | 2.86e-03 | 29 |
GO:00018377 | Oral cavity | OSCC | epithelial to mesenchymal transition | 82/7305 | 157/18723 | 5.09e-04 | 2.98e-03 | 82 |
GO:00452293 | Oral cavity | OSCC | external encapsulating structure organization | 147/7305 | 304/18723 | 5.30e-04 | 3.08e-03 | 147 |
GO:00430623 | Oral cavity | OSCC | extracellular structure organization | 146/7305 | 302/18723 | 5.59e-04 | 3.23e-03 | 146 |
GO:19030552 | Oral cavity | OSCC | positive regulation of extracellular matrix organization | 18/7305 | 25/18723 | 8.47e-04 | 4.47e-03 | 18 |
GO:00071629 | Oral cavity | OSCC | negative regulation of cell adhesion | 145/7305 | 303/18723 | 9.95e-04 | 5.18e-03 | 145 |
GO:00107173 | Oral cavity | OSCC | regulation of epithelial to mesenchymal transition | 54/7305 | 99/18723 | 1.21e-03 | 6.10e-03 | 54 |
GO:003003819 | Oral cavity | OSCC | contractile actin filament bundle assembly | 57/7305 | 106/18723 | 1.42e-03 | 6.84e-03 | 57 |
GO:004314919 | Oral cavity | OSCC | stress fiber assembly | 57/7305 | 106/18723 | 1.42e-03 | 6.84e-03 | 57 |
GO:003223119 | Oral cavity | OSCC | regulation of actin filament bundle assembly | 56/7305 | 105/18723 | 1.99e-03 | 9.23e-03 | 56 |
GO:006104116 | Oral cavity | OSCC | regulation of wound healing | 69/7305 | 134/18723 | 2.19e-03 | 9.95e-03 | 69 |
GO:00328863 | Oral cavity | OSCC | regulation of microtubule-based process | 115/7305 | 240/18723 | 2.95e-03 | 1.28e-02 | 115 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PHLDB2 | SNV | Missense_Mutation | novel | c.1172N>T | p.Asp391Val | p.D391V | Q86SQ0 | protein_coding | deleterious(0) | benign(0.203) | TCGA-A7-A425-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | PD |
PHLDB2 | SNV | Missense_Mutation | novel | c.3502N>A | p.Asp1168Asn | p.D1168N | Q86SQ0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PHLDB2 | SNV | Missense_Mutation | | c.359N>A | p.Gly120Glu | p.G120E | Q86SQ0 | protein_coding | tolerated_low_confidence(0.09) | benign(0.018) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PHLDB2 | SNV | Missense_Mutation | | c.1708N>G | p.Ile570Val | p.I570V | Q86SQ0 | protein_coding | tolerated(0.1) | benign(0.255) | TCGA-B6-A0WV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PHLDB2 | SNV | Missense_Mutation | | c.604C>T | p.Pro202Ser | p.P202S | Q86SQ0 | protein_coding | deleterious(0) | possibly_damaging(0.549) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PHLDB2 | SNV | Missense_Mutation | | c.1690N>C | p.Glu564Gln | p.E564Q | Q86SQ0 | protein_coding | deleterious(0.05) | benign(0.388) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PHLDB2 | SNV | Missense_Mutation | | c.1608N>T | p.Arg536Ser | p.R536S | Q86SQ0 | protein_coding | tolerated(0.07) | benign(0.057) | TCGA-D8-A1XG-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PHLDB2 | SNV | Missense_Mutation | | c.3134N>T | p.Ala1045Val | p.A1045V | Q86SQ0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
PHLDB2 | SNV | Missense_Mutation | novel | c.7N>A | p.Glu3Lys | p.E3K | Q86SQ0 | protein_coding | deleterious_low_confidence(0) | benign(0.214) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PHLDB2 | SNV | Missense_Mutation | novel | c.3132N>T | p.Gln1044His | p.Q1044H | Q86SQ0 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-LQ-A4E4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | PD |